Published in:
01-06-2013 | Original Article
Effects of pravastatin, atorvastatin, and rosuvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia
Published in: Diabetology International | Issue 2/2013
Login to get accessAbstract
Aims/introduction
We investigated the effects of three different statins in patients with type 2 diabetes mellitus and hypercholesterolemia.
Materials and methods
Patients with type 2 diabetes mellitus and low-density lipoprotein-cholesterol level of more than or equal to 100 mg/dL were treated at random with either atorvastatin (10 mg/day, n = 42), rosuvastatin (5 mg/day, n = 37) or pravastatin (10 mg/day, n = 38) for 3 months and changes in serum lipid profile and inflammatory markers were assessed.
Results
Low-density lipoprotein-cholesterol, small dense low-density lipoprotein and remnant-like particle cholesterol were significantly decreased from baseline in 3 groups. Atorvastatin and rosuvastatin significantly decreased high-sensitivity C-reactive protein. Rosuvastatin significantly decreased monocyte chemoattractant protein-1, while atorvastatin significantly increased estimated glomerular filtration rate (eGFR), but there were no significant intergroup differences in both parameters.
Conclusions
Atorvastatin and rosuvastatin significantly highly decreased low-density lipoprotein-cholesterol, remnant-like particle cholesterol, small dense low-density lipoprotein as well as high-sensitivity C-reactive protein than pravastatin and atorvastatin also had a potency in improve eGFR in patients with type 2 diabetes mellitus.